Literature DB >> 26578723

Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al.

L Goldwirt1, I Chami2, J-P Feugeas3, C Pages2, F Brunet-Possenti2, C Allayous2, B Baroudjian2, I Madelaine4, H Sauvageon5, S Mourah5, C Lebbé2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26578723     DOI： 10.1093/annonc/mdv538

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Authors:  Fanny Garlan; Benoit Blanchet; Nora Kramkimel; Alicja Puszkiel; Jean-Louis Golmard; Gaelle Noe; Nicolas Dupin; Pierre Laurent-Puig; Michel Vidal; Valerie Taly; Audrey Thomas-Schoemann
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.493

Review 2.  Clinical Pharmacokinetics of Vemurafenib.

Authors:  Weijiang Zhang; Dominik Heinzmann; Joseph F Grippo
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

3.  Precision Dosing of Targeted Therapies Is Ready for Prime Time.

Authors:  Neeltje Steeghs; Alwin D R Huitema; Stefanie L Groenland; Remy B Verheijen; Markus Joerger; Ron H J Mathijssen; Alex Sparreboom; Jos H Beijnen; Jan H Beumer
Journal:  Clin Cancer Res       Date:  2021-09-21       Impact factor: 12.531

4.  Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma.

Authors:  Ashley M Hopkins; Michael J Sorich; Ganessan Kichenadasse; Jim Henry Hughes; John O Miners; Arduino A Mangoni; Andrew Rowland
Journal:  Cancer Chemother Pharmacol       Date:  2019-11-30       Impact factor: 3.333

Review 5.  Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Authors:  Remy B Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema
Journal:  Clin Pharmacol Ther       Date:  2017-09-07       Impact factor: 6.875

Review 6.  Therapeutic drug monitoring of oral targeted antineoplastic drugs.

Authors:  Anna Mueller-Schoell; Stefanie L Groenland; Oliver Scherf-Clavel; Madelé van Dyk; Wilhelm Huisinga; Robin Michelet; Ulrich Jaehde; Neeltje Steeghs; Alwin D R Huitema; Charlotte Kloft
Journal:  Eur J Clin Pharmacol       Date:  2020-11-09       Impact factor: 2.953

7.  The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study.

Authors:  Lotte M Knapen; Rutger H T Koornstra; Johanna H M Driessen; Bas van Vlijmen; Sander Croes; Stein Schalkwijk; Angela Colbers; Winald R Gerritsen; David M Burger; Frank de Vries; Nielka P van Erp
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

8.  Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.

Authors:  Stefanie D Krens; Eric van der Meulen; Frank G A Jansman; David M Burger; Nielka P van Erp
Journal:  Biomed Chromatogr       Date:  2020-01-13       Impact factor: 1.902

9.  Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.

Authors:  Fatemeh Aghai; Sebastian Zimmermann; Max Kurlbaum; Pius Jung; Theo Pelzer; Hartwig Klinker; Nora Isberner; Oliver Scherf-Clavel
Journal:  Anal Bioanal Chem       Date:  2020-11-06       Impact factor: 4.142
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.